NEXAVAR - Articles and news items


Bayer and Onyx report Phase 3 study results of NEXAVAR® (sorafenib) as adjuvant treatment for patients with liver cancer who have undergone surgery or local ablation

Industry news / 11 March 2014 / Amgen

Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma…

Amgen logo


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...